Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/ehjcvp/pvad072 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Are glucagon-like-peptide-1 (GLP-1) receptor agonists useful in treating Parkinson's disease (PD). Does the clinical trial with lixisenatide add anything?
Expert Opin Investig Drugs
January 2025
School of Pharmacy and Medical Sciences, Griffith University, Brisbane, Australia.
Introduction: Parkinson's disease (PD) is a common neurodegenerative disease. Glucagon-Like-Peptide-1 (GLP-1) receptor agonists decrease the incidence of developing PD, and are being considered for the treatment of PD.
Areas Covered: A phase 2 clinical trial of lixisenatide, a GLP-1 receptor agonist, in the early stages of PD.
Kidney and Cardiovascular Outcomes Among Patients With CKD Receiving GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of Randomized Trials.
Am J Kidney Dis
January 2025
Renal Division, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan; National Taiwan University Hospital Study Group of ARF (NSARF), Taipei, Taiwan.
Rationale & Objective: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) improve cardiac and kidney outcomes in patients with diabetes; however their efficacy in individuals with reduced estimated glomerular filtration rate (eGFR) is uncertain. This study evaluated the effects of GLP-1RAs on kidney and cardiovascular (CV) outcomes in patients with chronic kidney disease (CKD).
Study Design: Systematic review and meta-analysis of randomized controlled trials (RCTs) reported through May 25, 2024.
Glucagon-Like Peptide-1 Receptor Agonist Medications and Hair Loss: A Retrospective Cohort Study.
J Am Acad Dermatol
January 2025
Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, FL, 33133, USA.
Purpose: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have risen exponentially in usage and have been shown to exert neuroprotective and anti-inflammatory effects across multiple organ systems. This study investigates whether GLP-1RAs influence the risk for age-related ocular diseases.
Design: Retrospective cohort study.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!